Inspire Pharmaceuticals , a company with a 20-year history in the Triangle, has agreed to pay $6 million to settle a federal civil fraud claim that it marketed an eye treatment for uses that the U.S. Food and Drug Administration had not approved, according to the U.S. Attorney's Office for the Southern District of New York. The office said in a press release that Inspire "misleadingly focused on purported anti-inflammatory properties of AzaSite that were unsupported by substantial evidence or substantial clinical experience in order to cause doctors to prescribe AzaSite for for uses not covered by federal healthcare programs."